How To Overcome The Problem Of The Early ePRO Oversell

By Fred Martin, Chief Operating Officer

Does this sound familiar? You implemented ePRO during the pandemic, or maybe even before it, and were excited by the promise of better participant engagement, increased participant compliance, and greater efficiency. Yet, the reality did not live up to the hype.

While your vendor promised you a straightforward implementation, you found the actual process to be overly complicated, time-consuming, costly, and frustrating. You did not realize the expected benefits of ePRO, and maybe you have even reverted back to paper processes or are only using ePRO for your most complex studies.

Yet, in today’s environment, you also know that you need to reconsider your approach to PROs, given increasing regulations and trial scrutiny, the clinical need for patient-reported outcomes, and the ability to drive costs down and move off paper.